Resources

Diagnosis can be the first symptom of chronic diseases regardless of obesity.

Treatment method reduced the amount of liver fat more than standard treatment alone.

Screening, treatment delay may hasten or increase cardiovascular disease risk.

Prolonged use of medication increases risk of bowel condition, but exact cause yet to be determined.

By Sheri R. Colberg, PhD, FACSM

How active are you? Unless you’re exercising more than several hours a day already, you probably have room to add more in for additional health benefits. Exercise is about the best medicine that there is for so many health conditions, including diabetes. Being active helps manage emotional stress and stave off depression—far better than antidepressant medications and with no bad side effects. It naturally bestows your body with antioxidant effect, making you less likely to develop most types of cancer—or even the common cold.

How much higher is the rate of cardiovascular (CV) death among unmarried vs married patients who are at high CV risk, according to a recent study? A. 19% B. 28% C. 34% D. 45% E. 56% Follow the link for the answer.

For a patient with type 2 who has an A1c of 8% and is on metformin, has tried diet change and exercise, and is 25 pounds overweight, which of the following would you prefer: GLP-1, SGLT-2, or something else? Follow the link to share your opinion.

Man, 52 years of age, with obesity and type 2 diabetes, was switched from daily liraglutide (Victoza) 1.8mg to weekly semaglutide (Ozempic) 0.25mg. I was very clear with patient about the switch being from a daily injection to a weekly and that we would be increasing the semaglutide weekly.

In this week's Homerun Slides, a closer look at the Systolic Blood Pressure Intervention Trial (SPRINT).

The foregoing observations have detailed the best established risk factors associated with insulin resistance as well some novel emerging risk factors as additionally detailed in Table 23.2, including nutritional measures such as Vitamin D. These are not comprehensive but rather a selection of emerging pathways of interest. Clearly, future research should increasingly harness genetics as well as observational data to better determine causal risk pathways. Similarly, further data are needed to better determine the extent to which insulin resistance is, or is not, linked to cardiovascular risk.